Gammora, a new Human Immuno-Deficiency Virus (HIV) drug developed by Israeli researchers has passed its first human clinical trial.

At the end of the trial, the drug created by Zion Medical, an Israeli biotech company in collaboration with the Hebrew University in Jerusalem and Germany’s Sirion Biotech wiped out 99 percent of HIV infected cells in the human body.

According to a statement released by the company on Monday, Gammora, which was designed to attack and kill the HIV-infected cells in the human body without causing damage to the healthy cells was able to eliminate up to 90 per cent of the virus during the first four weeks of the trial.

In the trials, the researchers randomly assigned nine participating patients from the Ronald Bata Memorial Hospital in Uganda to receive different doses of Gammora between four to five weeks in July and August of this year.

“Most patients showed a significant reduction of the viral load of up to 90 per cent from the baseline during the first four weeks,” Dr. Esmira Naftalim, Zion Medical’s head of development said.

While the new HIV drug is still in its first stage of exploration, the results have already offered hope that a cure for the dreaded virus is possible.